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ABSTRACT  1 
Background: Although smoking and HPV infection are recognized as important risk 2 
factors for oropharyngeal cancer, how their joint exposure impacts oropharyngeal cancer 3 
risk is unclear. Specifically, whether smoking confers any additional risk to HPV positive 4 
oropharyngeal cancer is not understood.  5 
Methods: Using HPV serology as a marker of HPV-related cancer, we examined the 6 
interaction between smoking and HPV16 in 459 oropharyngeal (and 1445 oral cavity & 7 
laryngeal) cancer patients and 3024 control participants from two large European multi-8 
center studies. Odds ratios and credible intervals [CrI], adjusted for potential 9 
confounders, were estimated using Bayesian logistic regression.  10 
Results: Both smoking (OR [CrI]: 6.82 [4.52, 10.29]) and HPV seropositivity (OR [CrI]: 11 
235.69 [99.95, 555.74) were independently associated with oropharyngeal cancer. The 12 
joint association of smoking and HPV seropositivity was consistent with that expected on 13 
the additive scale (synergy index [CrI]: 1.32 [0.51, 3.45]), suggesting they act as 14 
independent risk factors for oropharyngeal cancer.  15 
Conclusions: Smoking was consistently associated with increase in oropharyngeal 16 
cancer risk in models stratified by HPV16 seropositivity. In addition, we report that the 17 
prevalence of oropharyngeal cancer increases with smoking for both HPV16-positive as 18 
well as HPV16-negative persons. The impact of smoking on HPV16-positive 19 
oropharyngeal cancer highlights the continued need for smoking cessation programs for 20 
primary prevention of head and neck cancer.  21 
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 1 
Key message 2 
The incremental risk due to smoking in HPV16-positive oropharyngeal cancer (if any) 3 
remains unclear. 4 
Pooling two large HNC studies with HPV serology data, we examined the relationship 5 
between these risk factors. 6 
We demonstrate that smoking was consistently associated with increased risk of 7 
oropharyngeal cancer regardless of HPV status. 8 
These data demonstrate that tobacco exposure remains an important risk factor of 9 
oropharyngeal cancer irrespective of HPV status. 10 
  11 
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INTRODUCTION 1 
It is estimated that nearly 600,000 new cancers of the oral cavity, pharynx and larynx, 2 
are diagnosed each year worldwide, contributing to approximately 325,000 deaths each 3 
year1. Collectively referred to as head and neck cancers (HNC), most are squamous cell 4 
in origin and are grouped together due to etiologic similarities2. While nearly 33% of 5 
HNC are attributed to smoking alone, alcohol alone is estimated to cause nearly 4%, 6 
and the largest proportion of cases are attributed to the joint exposure to smoking and 7 
alcohol, nearly 35%3, 4. Recently, infection by human papillomavirus (HPV), has been 8 
associated with a subset of HNCs arising at the base of tongue, tonsils and the 9 
oropharynx5, 6.  10 
HPV-positive oropharyngeal carcinoma (OPC) patients tend to be more often never 11 
smokers compared to HPV-negative patients7, 8. In addition, statistically non-significant 12 
associations between smoking and HPV-positive OPC, have led to the speculation that 13 
smoking is not an important risk factor for HPV-positive OPC9. However, it is noteworthy 14 
that up to 30% of HPV-positive HNC occurs among heavy smokers and alcohol 15 
drinkers8, 10. Further, previous analyses did not account for differing baseline risks by 16 
HPV status when interpreting the odds ratios (OR) for smoking. In addition, classification 17 
of HPV status has been an important challenge in such studies. We have previously 18 
demonstrated that circulating antibodies against HPV16 oncoprotein E6 constitute a 19 
highly specific marker of HPV16-related OPC, present in nearly 30% of OPC and less 20 
than 1% of controls11, 12, while antibodies against HPV16 capsid protein L1 are regarded 21 
as markers of past exposure13, 14. The rarity of OPC and the limited proportion of never 22 
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smokers necessitate large pooled analysis to examine the relationships between these 1 
risk factors.  2 
A significant proportion of OPC patients report a history of smoking at diagnosis (nearly 3 
80% in the US & EU)3, 4, 8, 15, therefore we examined whether smoking increases the risk 4 
of HPV16-positive OPC. Further, we examined the impact of smoking on the prevalence 5 
of OPC among HPV -positive and -negative persons. We also examined the association 6 
between smoking, alcohol intake, HPV16 and the risk of non-oropharyngeal HNC.  7 
MATERIALS AND METHODS 8 
Study sample  9 
This analysis included two studies of HPV serology and HNC, the Alcohol-Related 10 
Cancers and Genetic Susceptibility in Europe (ARCAGE) study and HNC case-control 11 
study nested within the European Prospective Investigation Into Cancer and Nutrition 12 
(EPIC) cohort. Briefly, the ARCAGE study was conducted during 2002 to 2005 and 13 
included 1292 pathologically confirmed primary HNCs and 1425 controls frequency 14 
matched for age, sex, and area of residence11, 16. Ever smokers were defined as 15 
individuals who smoked any tobacco product at least once a week for a year, while ever 16 
drinkers were those who reported ever consuming any alcoholic beverage17. The EPIC 17 
cohort recruited 521,330 individuals during 1992 and 2000, of whom 385,747 18 
participants contributed a blood sample18. This analysis included 612 incident HNC and 19 
1599 controls12. Two controls (one in Denmark) were randomly selected for each cancer 20 
patient from appropriate risk sets consisting of all cohort participants alive and free of 21 
cancer (except non-melanoma skin cancer) at the time of diagnosis of the index case. 22 
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Controls were matched on country, sex, date of blood collection (1 month, relaxed to 5 1 
months for sets without available controls), and date of birth (1 year, relaxed to 5 years 2 
for sets without available participants). Ever smokers were individuals who reported ever 3 
smoking any tobacco product in their lifetime, and ever drinkers were individuals who 4 
reported ever consuming any alcoholic beverage. Head neck cancers included cancers 5 
arising at the oral cavity (International Classification of Diseases for Oncology [ICD-O] 6 
C00.3–C00.9, C02.0–C06.9, C14.0-C14.9, excluding C02.4, C02.8, C02.9, C05.1, 7 
C05.2, C05.8, C05.9), oropharynx (ICD-O: C01, C02.4, C05.1-C05.2, C09, C10), 8 
hypopharynx and larynx (ICD-O: C13, C32), and non-specified and overlapping sites 9 
(ICD-O: C02.8, C02.9, CO5.8, C05.9, C32.8). Lymphomas were not included, and 10 
salivary gland cancers were omitted. This analysis included head and neck cancers of 11 
all histological subtypes, of which squamous cancers comprised the vast majority 12 
(~91%), and some other rarer non-squamous histologies (6%, in ARCAGE, and 9% in 13 
EPIC). Informed consent was obtained from all participants in both the studies, and the 14 
studies were approved by the ethical review boards at the participating centers and the 15 
International Agency for Research on Cancer. 16 
HPV serology  17 
HPV antibodies were assayed using the bead-based multiplex serology method as 18 
described elsewhere19. Testing was performed blind to the case-control status of the 19 
participants. Mean fluorescence intensity (MFI) values were dichotomized by applying 20 
thresholds derived from a cross-sectional study among Korean students of mean plus 5 21 
standard deviations (SD; for HPV16 E6) or the mean plus 3 SD excluding positive 22 
outliers (for HPV16 L1)20, as described previously11, 12. 23 
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Statistical analysis  1 
The overall associations between HPV16 (L1 and E6), smoking, alcohol intake and HNC 2 
risk were assessed by calculating odds ratios (ORs) and their corresponding 95% 3 
confidence intervals (CIs). These models included age, sex, smoking status (never, 4 
former, current), alcohol consumption (never, ever plus ethanol grams/ day at 5 
recruitment), and country as covariates. Since certain combinations of exposures were 6 
very rare (e.g.: HPV16 E6-positive never smoking control subjects), Bayesian logistic 7 
regression models were used to calculate ORs and corresponding 95% credible 8 
intervals [CrI]. These models use a prior distribution to shrink or penalize the regression 9 
coefficients, thus providing more stable estimates than maximum likelihood methods. 10 
Following Gelman et al.21, all regression inputs were centered, and continuous inputs 11 
were re-scaled to have a standard deviation of 0.5. All regression coefficients were then 12 
modeled with a weakly informative Cauchy prior distribution with mean 0 and scale 2.5, 13 
with the exception of the intercept, which was given a weaker Cauchy prior with scale 14 
10. These models were fitted using the bayesglm function in the R package ARM21, 22. In 15 
these analyses, former and current smokers were combined as ever smokers, and given 16 
the few participants who reported never consumption of any alcoholic beverage; 17 
individuals who consumed 7 grams or less of ethanol (equivalent of half a drink) per day 18 
were considered the reference. Since the results from ARCAGE and EPIC studies were 19 
similar, data were pooled in order to obtain more precise estimates. Interactions 20 
between smoking, alcohol intake and HPV16 were examined by the inclusion of an 21 
interaction term in the penalized regression models. Additive interactions were evaluated 22 
by estimating the synergy index (SI)23. The prevalence of OPC by categories of smoking 23 
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and HPV16 were calculated based on the ORs from the fitted models and assumed 1 
population prevalence of 0.003, based on the cumulative risk for pharyngeal cancer 2 
among men and women combined, in more developed regions of the world24. All 3 
statistical analyses were performed using Stata version 11.2 (Stata Corporation, College 4 
Station, TX, USA) and R version 3.1.025.  5 
RESULTS 6 
Study profile  7 
A total of 1904 HNC patients included 459 OPC, 1445 non-oropharyngeal HNCs and 8 
3024 control subjects. Of these, 1292 HNC cases and 1425 controls were from the 9 
ARCAGE study and 612 HNC cases and 1599 controls from the EPIC study. OPC 10 
patients were similar to HNC patients as they tended to be more often men, current 11 
smokers and current drinkers (table I).  12 
Main effects of smoking, alcohol consumption and HPV antibodies in OPC 13 
HPV16 E6-positivity was observed in 0.7% of 3024 controls and 31.6% of 459 OPC 14 
subjects, and was strongly associated with OPC risk (OR (95% CI): 147.31 (83.07, 15 
361.24)). The odds of OPC was higher among current smokers compared to never 16 
smokers (OR (95% CI): 5.34 (3.89, 7.33)). Consumption of 28 or more grams of ethanol 17 
per day (2 or more drinks per day) was also associated with increased risk of OPC (OR 18 
(95% CI): 2.43 (1.77, 3.33)) (figure I).  19 
Combined effects of smoking and HPV16 in OPC 20 
12 
 
To understand the combined effects of smoking and HPV16 in OPC, we examined the 1 
relative odds of OPC given smoking and HPV16 status (table II). Compared with HPV16 2 
E6-negative never smokers, ever smoking was associated with 6.82 times increased 3 
OPC risk (95% CrI: 4.52, 10.29), while HPV16 E6-positivity alone was associated with 4 
235.69 times increased odds (95% CrI: 99.95, 555.74). HPV16 E6-positive ever 5 
smokers had 355.82 times higher OPC risk (95% CrI: 177.0, 715.30) compared to 6 
individuals negative for both risk factors. HPV16 E6-positivity and smoking appeared to 7 
interact on a less than multiplicative scale (OR [95% CrI] for the interaction term: 0.22 8 
[0.08, 0.62]). The SI for the interaction was calculated to be 1.32 (95% CrI: 0.51, 3.45), 9 
suggesting that the risks associated with HPV16 E6 and smoking might be additive. 10 
Interestingly, similar results were observed when HPV16 L1-positivity was examined 11 
(OR [95% CrI] for the multiplicative interaction term: 0.23 [0.13, 0.43], SI [95% CrI]: 0.75 12 
[0.51, 1.12]) (table II). These results remained unchanged when analyses were 13 
restricted to squamous cell cancers of the oropharynx (supplementary table V). In 14 
models stratified by HPV status (supplementary table I, model 1), we observed that OPC 15 
risk increased with the number of cigarettes smoked per day (CPD) among HPV16 L1-16 
negatives (OR [95%CrI] for >15 CPD: 8.71 [6.01, 12.64]), as well as HPV16 E6-17 
negatives (OR [95%CrI] for >15 CPD: 10.69 [7.06, 16.20]). Among HPV16-positives, we 18 
observed no additional increase in OPC risk with smoking dose (supplementary table I, 19 
model 1). The limited proportion of HPV16-positive controls in these comparisons is 20 
noteworthy, while 2.5% of HPV16 L1-positive controls reported smoking >15 CPD, this 21 
proportion was down to only 0.2% among HPV16 E6-positives (supplementary table I, 22 
model 2). Our previous analysis of predictors of HPV16 E6-positivity among cancer-free 23 
individuals suggested that the possibility of an underlying undiagnosed cancer cannot be 24 
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ruled out in such subjects26. Therefore, we excluded all HPV16 E6-positive controls 1 
under the assumption that they could be false positives or harbor other undiagnosed 2 
HPV-related cancer. We then compared HPV16 E6-positive cases with HPV16 E6-3 
negative controls to clarify whether smoking might confer any further risk in HPV16-4 
positive OPC (table III). Results indicate that the OPC risk among HPV16-positive 5 
persons increased with smoking. Compared with never smokers, both former smokers 6 
(OR [95% CrI]: 1.49 [0.95, 2.36]) and current smokers (OR [95% CrI]: 1.86 [1.17, 2.96]) 7 
were at increased OPC risk. However, we observed a modest trend toward increased 8 
OPC risk with smoking dose (OR [95% CrI] for ≤15 CPD: 1.61 [1.03, 2.54] and OR [95% 9 
CrI] for >15 CPD: 1.77 [1.11, 2.84]). 10 
Relatedly, the relationship between smoking and the risk of HPV-positivity remains 11 
poorly understood. It remains unclear whether smoking may enhance HPV exposure 12 
and/or infection. Using HPV seropositivity as the end-point, Kelsey et al have recently 13 
demonstrated that younger smokers were more likely to be seropositive for HPV16 L1 14 
than older smokers27. We sought to understand whether any age-dependent association 15 
existed between smoking and HPV seropositivity in this study. Briefly, in analysis 16 
restricted to controls, age was divided into tertiles as young (<54), intermediate (54-62) 17 
and old (>62 years of age) subjects. We then examined the association between these 18 
age categories and HPV16 seropositivity by smoking status. Overall age did not appear 19 
to be strongly associated with HPV seropositivity, either HPV16 L1 (OR [95% CI]: 0.78 20 
[0.56, 1.09]) or HPV16 E6 (OR [95% CI]: 0.67 [0.22, 2.02]), albeit based on small 21 
numbers. Current smoking, on the other hand, modestly reduced the risk of HPV16 L1 22 
seropositivity (OR [95% CI]: 0.79 [0.62, 1.00]) but not HPV16 E6 (OR [95% CI]: 1.0 23 
14 
 
[0.67, 1.51]) (supplementary table VI). We found no evidence for an interaction between 1 
age and smoking towards HPV16 seropositivity (supplementary table VII). Similarly, 2 
when stratified by smoking, age was not associated with risk of HPV16 L1 seropositivity 3 
in former (OR [95% CI]: 0.91 [0.56, 1.48]) or current smokers (OR [95% CI]: 1.36 [0.79, 4 
2.36]) (supplementary table VIII). 5 
OPC prevalence by smoking and HPV16 status 6 
In order to provide a simple appreciation of the joint importance of HPV infection and 7 
tobacco smoking, we estimated the prevalence of OPC given smoking and HPV16 E6 8 
status, assuming an overall OPC population prevalence of 0.003. OPC prevalence 9 
among HPV16 E6-negative never smokers was negligible (0.05%; 95% CrI: 0.03%, 10 
0.07%), which increased to 0.13% (95% CrI: 0.08%, 0.20%) in former smokers, and 11 
further increased to 0.54% (95% CrI: 0.36%, 0.80%) in current smokers. Similarly, 12 
among HPV16-positive participants, the baseline prevalence in never smokers was 13 
8.94% (95% CrI: 4.20%, 18.01%), 11.58% (95% CrI: 5.38, 23.19%) in former smokers, 14 
and further increased to 17.68% (95% CrI: 7.29%, 36.95%) in current smokers (figure II).  15 
Non-oropharyngeal HNC risk factors 16 
For non-oropharyngeal HNC, current smoking (OR [95%CrI]: 6.82 [5.51, 8.44]), alcohol 17 
consumption of >28 grams per day (OR [95%CrI]: 2.31 [1.87, 2.85]), and HPV16 E6-18 
positivity were associated with increased risk on non-oropharyngeal HNC (OR [95%CrI]: 19 
2.57 [1.24, 5.33]), while HPV16 L1-positivity was not (OR [95%CrI]: 1.05 [0.82, 1.35]) 20 
(supplementary figure I). No interaction was observed between HPV16 and smoking for 21 
non-oropharyngeal HNC (supplementary table II). Alcohol consumption and HPV16 22 
15 
 
antibody status did not appear to interact to affect risk of either oropharyngeal or non-1 
oropharyngeal HNC (supplementary tables III and IV). Study-specific associations 2 
between smoking, alcohol intake, HPV16 and OPC risk and non-oropharyngeal HNC 3 
risk are presented in supplementary figures II to V. 4 
DISCUSSION 5 
This study supports the notion that smoking and alcohol are important risk factors for all 6 
HNC subsites, while HPV16 infection is relevant at the oropharynx. We demonstrate that 7 
smoking increases the risk of OPC, irrespective of HPV16 status. Importantly, OPC 8 
remains higher in smokers compared with never smokers, among both HPV16-positive 9 
and -negative persons. 10 
The manner in which two (or more) distinct risk factors interact to influence disease risk 11 
can be tested by examining the joint effects. Biologically, components (or exposures) 12 
that lie within the same causal pathway are thought to interact, implying that disease will 13 
not occur (or will occur at the population baseline rates) in the absence of any one of the 14 
exposures. Statistically, the combined effect may be quantified on the multiplicative or 15 
additive scale. Most risk factors interact in greater than a multiplicative scale. For 16 
example, while smoking and alcohol consumption are each associated with substantially 17 
increased risks of HNC, smokers who also consume alcohol experience risk far greater 18 
risk than the product of the two3, 4. Such a “supermultiplicative” risk is often interpreted to 19 
indicate that the risk factors potentiate the carcinogenic effects of each other. Truly 20 
additive effects, where the combined risk is similar to the sum of individual risks are rare. 21 
Such additive interactions are thought to indicate independence of risk factors. In this 22 
16 
 
study we observe that the joint effect of HPV16 (L1 and E6 antibody status) and 1 
smoking are consistent with that expected on the additive scale. This result suggests 2 
that HPV16 and smoking are independent risk factors for OPC, a conclusion supported 3 
by previous studies7, 9, 28-30. However, that the association of smoking with risk of OPC in 4 
HPV16-positives has not been statistically significant has been interpreted as the 5 
absence of risk due to smoking, and has led to the speculation that presence of HPV16 6 
could protect against the adverse effects of smoking9. In this study, we clearly 7 
demonstrate that the OPC risk increases with smoking even in the context of HPV16-8 
positive OPC. The consistency of these observations when considering HPV16 L1 or 9 
HPV16 E6-positivity as markers of HPV16 status further strengthens our conclusions. 10 
These results would also seem to suggest that smoking may induce molecular changes 11 
in HPV16-positive OPC. This hypothesis is supported by results from the RTOG trial 12 
where OPC patients’ were stratified into three distinct risk-of-death groups; while HPV-13 
positive never smokers experienced the best prognosis and HPV-negative smokers the 14 
worst, the combined presence of smoking and HPV constituted an “intermediate” risk 15 
group31.  16 
Unlike the recently published report27, we found no evidence for an interaction between 17 
age and smoking in the risk of HPV seropositivity. This largely implies age appears not 18 
be associated with HPV seropositivity regardless of smoking status. Contrarily, the 19 
association between smoking and HPV seropositivity, either for L1 or E6, does not 20 
appear to vary with age in this study. In other words, smoking did not appear to alter 21 
either exposure or infection to HPV16 (L1 and E6, respectively) differentially by age in 22 
this study. 23 
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Further, our data emphasize that it remains critical to interpret relative risks in the 1 
context of the dramatically differing baseline risks between HPV16-positive and -2 
negative people. We estimated the absolute difference in OPC prevalence between 3 
never and current smokers to be 0.5% in HPV16 E6-negative individuals, and 8.8% in 4 
HPV16 E6-positives, re-emphasizing the importance of smoking regardless of HPV16 5 
status. These data suggest that smoking remains an important risk factor for OPC, at 6 
least in Europe where almost a quarter of the patients are both HPV16 positive and 7 
report smoking history at diagnosis. In this study, we did not observe a strong interaction 8 
between alcohol consumption and HPV16. This is perhaps unsurprising given that 9 
alcohol appears to affect HNC risk at higher doses and primarily in the presence of 10 
tobacco smoking3, 4.  11 
To the best of our knowledge, this constitutes the largest study examining the joint 12 
effects of smoking and HPV16 infection in OPC. It is important to note that antibody 13 
status is a systemic marker, and might therefore reflect infection in any location in the 14 
body rather than an oropharyngeal infection specifically. However, we and others have 15 
previously demonstrated HPV16 E6 as a highly specific11, 12, 28-31 and likely sensitive 16 
marker for HPV16-related OPC11, 12. Further, since this uncertainty applies to both cases 17 
and controls, it is not expected to lead to biased comparisons. Further, self-reported 18 
data on alcohol and tobacco use was used, thus may contribute to some measurement 19 
error, especially in the retrospective case-control study.  20 
In summary, these results indicate that smoking and HPV16 follow independent 21 
pathways towards OPC. The impact of smoking on HPV16-positive OPC may have 22 
18 
 
important implications for treatment, survival and recurrence of OPCs, and re-1 
emphasizes the continuing need for tobacco cessation programs.  2 
 3 
  4 
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Table I: Characteristics of the study population 
 
ARCAGE Study 
 
EPIC study 
 
Controls OPC Non-OPC 
 
Controls OPC Non-OPC 
 
N (%) N (%) N (%) 
 
N (%) N (%) N (%) 
  n=1425 n=324 n=968 
 
n=1599 n=135 n=477 
Age group 
       <55 454 (31.9) 106 (32.7) 295 (30.5)  654 (40.9) 76 (56.3) 183 (38.4) 
≥55-  59 241 (16.9) 84 (25.9) 181 (18.7)  400 (25.0) 29 (21.5) 131 (27.4) 
≥60- 64 210 (14.7) 53 (16.4) 155 (16.0)  325 (20.3) 24 (17.8) 113 (23.7) 
≥65 520 (36.5) 81 (25.0) 337 (34.8)  220 (13.8) 6 (4.4) 50 (10.5) 
Sex 
       Men 1059 (74.3) 252 (77.8) 782 (80.8) 
 
1105 (69.1) 89 (65.9) 351 (73.6) 
Women 366 (25.7) 72 (22.2) 186 (19.2) 
 
494 (30.9) 46 (34.1) 126 (26.4) 
Smoking status 
         Never       516 (36.2) 33 (10.2) 107 (11.1) 
 
631 (39.5) 34 (25.2) 76 (15.9) 
  Former      475 (33.3) 77 (23.8) 225 (23.2) 
 
553 (34.6) 40 (29.6) 115 (24.1) 
Current 434 (30.5) 214 (66.1) 636 (65.7) 
 
385 (24.1) 60 (44.4) 282 (59.1) 
Missing 
    
30 (1.9) 1 (0.7) 4 (0.8) 
Alcohol consumption 
      Never                172 (12.1) 11 (3.4) 62 (6.4) 
 
55 (3.4) 3 (2.2) 14 (2.9) 
Former             134 (9.4) 50 (15.4) 131 (13.5) 
 
132 (8.3) 16 (11.9) 48 (10.1) 
Current 1118 (78.5) 263 (81.2) 775 (80.1) 
 
1025 (64.1) 93 (68.9) 319 (66.9) 
Missing 1 (0.1) 
   
387 (24.2) 23 (17.0) 96 (20.1) 
Level of education 
      Primary school  444 (31.2) 112 (34.6) 412 (42.6) 
 
643 (41.5) 51 (38.4) 206 (44.4) 
Secondary/ 
Technical school 834 (58.5) 193 (59.6) 518 (53.5) 
 
604 (38.9) 56 (42.1) 190 (40.9) 
University 
degree 147 (10.3) 19 (5.9) 37 (3.8) 
 
302 (19.5) 26 (19.6) 68 (14.7) 
Missing 
  
1 (0.1) 
    Cancer site 
       Oral cavity - 
 
411 (42.5) 
   
180 (37.7) 
Oropharynx 
 
324 (100) 
   
135 (100) 
 Larynx 
  
534 (55.2) 
   
247 (51.8) 
Overlapping sites    23 (2.4)       50 (10.5) 
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Table II: Interaction between HPV16 antibodies and smoking in the risk of oropharynx 
cancer 
HPV16 
Antibody 
Smoking 
status 
Control Oropharynx cancer 
N (%) N (%) OR [95% CrI]* 
  
(n=2994) (n=458) 
 HPV16 E6 serology 
Negative Never 1140 (38.1) 25 (5.5) Reference 
Negative Ever 1834 (61.3) 288 (62.9) 6.82 [4.52, 10.29]  
Positive Never 7 (0.23) 42 (9.2) 235.69 [99.95, 555.74]  
Positive Ever 13 (0.43) 103 (22.5) 355.82 [177.00, 715.30]  
Interactionⱡ 
  
0.22 [0.08- 0.62]  
Synergy Index§     1.32 [0.51- 3.45] 
HPV16 L1 serology 
Negative Never 1003 (33.5) 33 (7.2) Reference 
Negative Ever 1631 (54.5) 324 (70.7) 6.73 [4.04, 11.22] 
Positive Never 144 (4.8) 34 (7.4) 5.80 [4.03, 8.36] 
Positive Ever 216 (7.2) 67 (14.6) 9.15 [5.92, 14.13] 
Interactionⱡ 
   
0.23 [0.13, 0.42] 
Synergy Index§      0.75 [0.51, 1.12] 
* OR & credible intervals from penalized regression model on ARCAGE and EPIC studies 
combined 
ⱡ represent OR & credible interval of multiplicative interaction evaluated by inclusion of an 
interaction term in the penalized regression model.  
§ synergy index (SI), a test of additive interaction providing evidence that the combined 
exposure is additive (SI=1), super additive (SI>1) or less than additive (SI<1). 
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Table III: Smoking associated risk of HPV16-related oropharyngeal cancer 
 
Controls* HPV16 E6 positive OPC 
 (N=2974) (N=145) 
Exposure N (%) N (%) OR [95% CrI]§ 
Smoking status    
Never smoker 1140 (38.3) 42 (29.0) Reference 
Former smoker 1020 (34.3) 52 (35.9) 1.49 [0.95, 2.36] 
Current smoker 814 (27.4) 51 (35.2) 1.86 [1.17, 2.96] 
Smoking intensity 
Never smoker 1140 (41.9) 42 (30.4) Reference 
≤15 cig/day 805 (29.6) 47 (34.1) 1.61 [1.03, 2.54] 
>15 cig/day 776 (28.5) 49 (35.5) 1.77 [1.11, 2.84] 
Alcohol consumption (grams/day) 
≤7  927 (35.8) 48 (35.0) Reference 
0.7- 28  993 (38.3) 51 (37.2) 0.91 [0.59, 1.41] 
>28  670 (25.9) 38 (27.7) 0.96 [0.58,1.58] 
*HPV16 E6 negative controls only were included 
§ adjusted for age, sex, country and alcohol consumption status or smoking status as appropriate  
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Figure I: Main effects for smoking, alcohol and HPV16 antibodies and oropharyngeal 
cancer risk 
Legends: For HPV16, corresponding antibody negatives were considered the reference. 
ⱡ 30 controls and 1 OPC patient were missing smoking status information, and 416 controls and 
25 OPC patients were missing data on frequency of alcohol consumption. 
*ORs adjusted for age, sex, smoking status (never, former, current), alcohol consumption 
(never, ever drinkers grams per day as continuous variable) and country as appropriate. 
 
 
Figure II: Estimated prevalence of oropharyngeal cancer by smoking and HPV16 status 
Legends: The prevalence of oropharyngeal cancer by categories of smoking and HPV16 was 
calculated based on ORs from a model including interaction terms between smoking categories 
and HPV16 E6 positivity, and an assumed population prevalence of 0.003. 


